mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
Scientific Papers found: Click to Expand⟱
3631- Cro,    Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease
- in-vitro, AD, HT22 - in-vivo, AD, NA
*ROS↓, *Ca+2↓, *BAX↓, *BAD↓, *Casp3↓, *cognitive↑, *memory↑, *Aβ↓, *GPx↑, *SOD↑, *ChAT↑, *Ach↑, *AChE↓, *ROS↓, *p‑Akt↑, *p‑mTOR↑, *neuroP↑,
3861- CUR,    Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
- Review, Var, NA
*antiOx↑, *Inflam↓, PI3K↓, Akt↓, mTOR↓, Wnt↓, β-catenin/ZEB1↓, NF-kB↓, HH↓, NOTCH↓, JAK↓, STAT3↓, ADAM10↓,
3795- CUR,    Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence
- Review, AD, NA
*antiOx↑, *Inflam↓, *AntiAge↑, *AMPK↑, *SIRT1↑, *NF-kB↓, *mTOR↓, *NLRP3↓, *NADPH↓, *ROS↓, *COX2↓, *MCP1↓, *IL1β↓, *IL17↓, *IL23↓, *TNF-α↓, *MPO↓, *IL10↑, *lipid-P↓, *SOD↑, *Aβ↓, *p‑tau↓, *GSK‐3β↓, *CDK5↓, *TXNIP↓, *NRF2↑, *NQO1↑, *HO-1↑, *OS↑, *memory↑, *BDNF↑, *neuroP↑, *BACE↓, *AChE↓, *LDL↓,
140- CUR,    Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
- in-vitro, Pca, PC3
CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,
123- CUR,    Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells
- in-vitro, Colon, LoVo - in-vitro, Colon, COLO205 - in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1
NF-kB↓, ATF3↑, HO-1↑, Wnt↓, Akt↓, mTOR↓, PTEN↑, Apoptosis↑, TGF-β↓, PPARγ↑,
15- CUR,  UA,    Effects of curcumin and ursolic acid in prostate cancer: A systematic review
- Review, Pca, NA
NF-kB↝, Akt↝, AR↝, Apoptosis↝, Bcl-2↝, Casp3↝, BAX↝, P21↝, ROS↝, Bcl-xL↝, JNK↝, MMP2↝, P53↝, PSA↝, VEGF↝, COX2↝, cycD1/CCND1↝, EGFR↝, IL6↝, β-catenin/ZEB1↝, mTOR↝, NRF2↝, AP-1↝, Cyt‑c↝, PI3K↝, PTEN↝, Cyc↝, TNF-α↝,
476- CUR,    The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer
- in-vitro, PC, PATU-8988 - in-vitro, PC, PANC1
TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,
471- CUR,    Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
Apoptosis↑, TumAuto↑, p62↓, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Casp9↑, PARP↑, ATG3↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑,
435- CUR,    Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway
- in-vitro, Lung, A549
Apoptosis↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1↑, p62↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, p‑mTOR↓,
457- CUR,    Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,
425- CUR,    Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
CDC25↓, cDC2↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, BAX↑, Casp3↑,
452- CUR,    Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells
- vitro+vivo, HNSCC, SCC9 - vitro+vivo, HNSCC, FaDu - vitro+vivo, HNSCC, HaCaT
TumCCA↑, PI3k/Akt/mTOR↓, Casp3↑, EGFR↓, EGF↑, PRKCG↑, p‑Akt↓, p‑mTOR↓, RPS6KA1↓, EIF4E↓, proCasp3↓,
445- CUR,    Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,
168- CUR,    Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
- in-vitro, Pca, PC3
Akt↓, mTOR↓, AMPK↑, TAp63α↑, TumCP↓,
4710- CUR,    mTOR_signaling_pathway">Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway
- in-vitro, Lung, A549
TumCMig↓, TumCI↓, miR-206↑, p‑mTOR↓, p‑Akt↓,
2304- CUR,    Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition
- in-vitro, Lung, H1299 - in-vitro, BC, MCF-7 - in-vitro, Cerv, HeLa - in-vitro, Pca, PC3 - in-vitro, Nor, HEK293
Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, mTOR↓, Hif1a↓, selectivity↑, Dose↝, tumCV↓,
2307- CUR,    Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin
- in-vitro, Colon, HT29 - in-vitro, Laryn, FaDu
PKM2↓, Warburg↓, mTOR↓, Hif1a↓, Glycolysis↓,
2821- CUR,    Antioxidant curcumin induces oxidative stress to kill tumor cells (Review)
- Review, Var, NA
*antiOx↑, *NRF2↑, *ROS↓, *Inflam↓, ROS↑, p‑ERK↑, ER Stress↑, mtDam↑, Apoptosis↑, Akt↓, mTOR↓, HO-1↑, Fenton↑, GSH↓, Iron↑, p‑JNK↑, Cyt‑c↑, ATF6↑, CHOP↑,
1869- DCA,    Dichloroacetate induces autophagy in colorectal cancer cells and tumours
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, Pca, PC3 - in-vitro, CRC, HT-29
LC3II↑, ROS↑, mTOR↓, MCT1↓, NADH:NAD↓, NAD↑, TumAuto↑, lactateProd↓, LDH↑,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
1442- Deg,    Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
- Review, Var, NA
PI3K/Akt↓, IKKα↓, AMP↓, mTOR↓, survivin↓, NF-kB↓, Apoptosis↑, TumCCA↑, toxicity↓, HSP90↓, Casp↑, TumCG↓, p27↑, cycE/CCNE↓, angioG↓, Hif1a↓, VEGF↓, *toxicity↑,
19- Deg,    Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1
HH↓, Gli1↓, PTCH1↓, Sufu↓, MMP2↓, MMP9↓, PI3K/Akt↓, HIF-1↓, VEGF↓, IKKα↓, NF-kB↓, EMT↓, AMPK↑, mTOR↓, survivin↓, TumCG↓, Apoptosis↑, TumCMig↓, TumCI↓,
2352- dietFMD,    Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
Warburg↓, mTOR↓, PKM2↓,
1844- dietFMD,    Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment
- Review, NA, NA
Risk↓, AMPK↑, Akt↓, mTOR↓, SIRT1↑, Hif1a↓, NRF2↓, SOD↑, ROS↑, IGF-1↓, p‑Akt↓, PI3K↑, GutMicro↑, OS↑, eff↝, ROS↑, TumCCA↑, *DNArepair↑, DNAdam↑,
1849- dietFMD,    The emerging role of fasting-mimicking diets in cancer treatment
- Review, Var, NA
TumCG↓, toxicity∅, BG↓, IGF-1↓, mTOR↓, M2 MC↓, eff↑, ChemoSen↑, QoL↑, RadioS↑, selectivity↑,
1852- dietFMD,  Chemo,    Starvation Based Differential Chemotherapy: 
A Novel Approach for Cancer Treatment
- Review, Var, NA
ChemoSideEff↓, *toxicity↓, mTOR↓, IGF-1↓, IGFBP1↑, BG↓, ROS↑,
1854- dietFMD,    How Far Are We from Prescribing Fasting as Anticancer Medicine?
- Review, Var, NA
ChemoSideEff↓, ChemoSen↑, IGF-1↓, IGFBP1↑, adiP↑, glyC↓, E-cadherin↑, MMPs↓, Casp3↑, ROS↑, ATP↓, AMPK↑, mTOR↓, ROS↑, Glycolysis↓, NADPH↓, OXPHOS↝, eff↑, eff↑, *RAS↓, *MAPK↓, *PI3K↓, *Akt↓, eff↑, ROS↑, Akt↑, Casp3↑,
1860- dietFMD,  Chemo,    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
- in-vitro, BC, SUM159 - in-vitro, BC, 4T1
PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,
2272- dietMet,    Methionine restriction - Association with redox homeostasis and implications on aging and diseases
- Review, Nor, NA
*OS↑, *mt-ROS↓, *H2S↑, *FGF21↑, *cognitive↑, *GutMicro↑, *IGF-1↓, *mTOR↓, *GSH↑, *SOD↑, *MDA↓, *NRF2↑, *HO-1↑, *NQO1↑, *GLUT4↑, *Glycolysis↑, *HK2↑, *PFK↑, *PKM2↑, *GlucoseCon↑, *ATF4↑, *PPARα↑, GSH↓, GSTs↑, ROS↑, *neuroP↑,
5068- dietSTF,    mTOR-autophagy axis regulation by intermittent fasting promotes skeletal muscle growth and differentiation
- in-vivo, Nor, NA
*glucose↓, ROS↑, LC3B↑, p62↓, p‑mTOR↓, p‑AMPK↑,
5069- dietSTF,    The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases
- Review, Var, NA
Risk↓, ChemoSen↑, RadioS↑, *Dose↝, *Dose↝, *Dose↝, *LDL↓, *CRP↓, *TNF-α↓, TumAuto↓, GLUT1↓, GLUT2↓, glucose↓, IGF-1↓, Insulin↓, mTOR↓, mTORC1↓, AMPK↑, Warburg↓, OXPHOS↑, ROS↑, DNAdam↑, JAK1↓, STAT↓, TumCP↓, QoL↑,
3708- dietSTF,    Fasting as a Therapy in Neurological Disease
*PGC-1α↑, *AMPK↑, *adiP↑, *glucose↓, *Insulin↓, *mTOR↓, *IL6↓, *TNF-α↓, *cognitive↑, *Inflam↓, *eff↑, *neuroP↑, ChemoSen↑, eff↓, chemoP↑, *eff↑,
1608- EA,    Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, Lung, A549 - in-vitro, Nor, HUVECs
eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,
1610- EA,    Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer
- Review, Cerv, NA
TumCCA↑, STAT3↓, P21↑, IGFBP7↑, Akt↓, mTOR↓, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑,
20- EGCG,    Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
- in-vivo, Liver, NA - in-vivo, Tong, NA
HH↓, Gli1↓, Smo↓, TNF-α↓, COX2↓, *antiOx↑, Hif1a↓, NF-kB↓, VEGF↓, STAT3↓, Bcl-2↓, P53↑, Akt↓, p‑Akt↓, p‑mTOR↓, EGFR↓, AP-1↓, BAX↑, ROS↑, Casp3↑, Apoptosis↑, NRF2↑, *H2O2↓, *NO↓, *SOD↑, *Catalase↑, *GPx↑, *ROS↓,
651- EGCG,    Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,
694- EGCG,    Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
- in-vitro, BC, MCF-7
Glycolysis↓, GAPDH↓, ROS↑, OCR↓, ECAR↓, mTOR↓, OXPHOS↓,
683- EGCG,    Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy
- Review, NA, NA
AMPK↑, TumCP↓, P21↑, mTOR↓, COX2↓,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
3244- EGCG,    Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells
AMPK↑, TumCP↓, P21↑, mTOR↓, CSCs↓, CD44↓, CD24↓,
3214- EGCG,    EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway
- in-vitro, Nor, MRC-5 - in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MDA-MB-231 - in-vitro, CRC, HCT116
mTOR↓, AMPK↑, selectivity↑, ROS↑, selectivity↑, HO-1↓, *NRF2↑, NRF2↓, *HO-1↑,
1323- EMD,    Anticancer action of naturally occurring emodin for the controlling of cervical cancer
- Review, Cerv, NA
TumCCA↑, DNAdam↑, mTOR↓, Casp3↑, Casp8↑, Casp9↑, TGF-β↑, SMAD3↓, p‑SMAD4↓, ROS↑, MMP↓, CXCR4↓, HER2/EBBR2↓, ER Stress↓, TumAuto↑, NOTCH1↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2849- FIS,    Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells
- in-vitro, Melanoma, U266
TumCD↑, TumCCA↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, p‑Akt↓, p‑mTOR↓, ROS↑, eff↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2860- FIS,    Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3 - in-vitro, Nor, hTERT-HPNE - in-vivo, NA, NA
AMPK↑, mTOR↑, UPR↑, ER Stress↑, selectivity↑, TumCP↓, PERK↑, ATF4↑, ATF6↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,

Showing Research Papers: 101 to 150 of 302
Prev Page 3 of 7 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 302

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ATF3↑, 1,   Fenton↑, 1,   GSH↓, 3,   GSTs↓, 1,   GSTs↑, 1,   HO-1↓, 1,   HO-1↑, 3,   hyperG↓, 1,   Iron↑, 1,   NRF2↓, 3,   NRF2↑, 1,   NRF2↝, 1,   OXPHOS↓, 1,   OXPHOS↑, 2,   OXPHOS↝, 1,   PYCR1↓, 1,   ROS↓, 3,   ROS↑, 28,   ROS↝, 1,   SOD↓, 1,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,   KLF5↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   CDC2↓, 1,   CDC25↓, 3,   EGF↓, 1,   EGF↑, 1,   FGFR1↓, 1,   Insulin↓, 1,   MEK↓, 1,   MMP↓, 5,   mtDam↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↑, 3,   p‑ACC-α↑, 1,   adiP↑, 1,   AMP↓, 1,   AMPK↑, 12,   p‑AMPK↑, 3,   CAIX↓, 1,   cMyc↓, 2,   ECAR↓, 1,   GAPDH↓, 1,   glucose↓, 1,   GlucoseCon↓, 2,   GLUT2↓, 1,   glyC↓, 1,   Glycolysis↓, 6,   lactateProd↓, 3,   LDH↓, 1,   LDH↑, 1,   NAD↑, 1,   NADH:NAD↓, 1,   NADPH↓, 1,   PDK1↓, 1,   PDKs↓, 1,   PI3K/Akt↓, 3,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 4,   PPARγ↑, 1,   p‑S6K↓, 1,   SIRT1↑, 1,   Warburg↓, 3,  

Cell Death ⓘ

Akt↓, 15,   Akt↑, 3,   Akt↝, 1,   p‑Akt↓, 10,   Apoptosis↑, 12,   Apoptosis↝, 1,   ASK1↑, 1,   BAD↑, 3,   BAX↑, 10,   BAX↝, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   Bcl-2↝, 1,   Bcl-xL↓, 2,   Bcl-xL↝, 1,   BIM↑, 4,   Casp↑, 4,   Casp3↑, 14,   Casp3↝, 1,   cl‑Casp3↑, 1,   proCasp3↓, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 4,   cl‑Casp9↑, 1,   Cyt‑c↑, 6,   Cyt‑c↝, 1,   Diablo↑, 3,   DR4↑, 1,   DR5↑, 2,   Fas↑, 1,   JNK↑, 1,   JNK↝, 1,   p‑JNK↑, 1,   MAPK↓, 1,   Mcl-1↓, 3,   MCT1↓, 1,   Myc↓, 1,   p27↑, 3,   p38↓, 1,   survivin↓, 2,   TRAIL↑, 1,   TumCD↑, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 2,   p70S6↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 3,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

ATF6↑, 2,   CHOP↑, 3,   ER Stress↓, 1,   ER Stress↑, 5,   GRP78/BiP↑, 1,   HSP27↓, 2,   HSP70/HSPA5↓, 3,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

ATG3↑, 2,   ATG5↑, 1,   Beclin-1↑, 3,   LC3‑Ⅱ/LC3‑Ⅰ↑, 2,   LC3B↑, 1,   LC3I↓, 1,   LC3II↑, 3,   LC3s↓, 1,   p62↓, 3,   p62↑, 2,   TumAuto↓, 1,   TumAuto↑, 6,  

DNA Damage & Repair ⓘ

DNAdam↑, 8,   NBR2↑, 1,   P53↑, 8,   P53↝, 1,   p73↑, 1,   PARP↑, 1,   cl‑PARP↑, 5,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 6,   CDK4↓, 5,   CDK4↑, 2,   Cyc↝, 1,   cycA1/CCNA1↓, 2,   cycD1/CCND1↓, 6,   cycD1/CCND1↝, 1,   cycE/CCNE↓, 3,   P21↑, 10,   P21↝, 1,   Securin↓, 1,   TAp63α↑, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

CD24↓, 1,   CD44↓, 1,   cDC2↓, 1,   cFos↓, 3,   CSCs↓, 2,   EIF4E↓, 1,   EMT↓, 6,   ERK↓, 1,   ERK↑, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   Gli1↓, 3,   p‑GSK‐3β↑, 1,   HH↓, 4,   IGF-1↓, 6,   IGFBP1↑, 2,   IGFBP7↑, 1,   miR-34a↑, 1,   mTOR↓, 33,   mTOR↑, 3,   mTOR⇅, 1,   mTOR↝, 1,   p‑mTOR↓, 10,   mTORC1↓, 4,   mTORC2↓, 1,   mTORC2↑, 1,   Nanog↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   OCT4↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 8,   PI3K↑, 3,   PI3K↝, 1,   PRKCG↑, 1,   PTCH1↓, 1,   PTEN↑, 3,   PTEN↝, 1,   RPS6KA1↓, 1,   Smo↓, 2,   STAT↓, 2,   STAT3↓, 3,   STAT6↓, 1,   Sufu↓, 1,   TCF↑, 1,   TumCG↓, 6,   Wnt↓, 5,  

Migration ⓘ

AP-1↓, 1,   AP-1↝, 1,   Ca+2↑, 3,   CAFs/TAFs↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   FAK↓, 1,   Fibronectin↓, 2,   Ki-67↓, 1,   KLF2↓, 1,   MET↓, 1,   miR-206↑, 1,   MMP1↓, 1,   MMP2↓, 6,   MMP2↝, 1,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 5,   MMPs↓, 1,   N-cadherin↓, 3,   NEDD9↓, 1,   PKA↓, 1,   SMAD3↓, 1,   p‑SMAD4↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TGF-β↑, 1,   TSC1↑, 1,   TumCI↓, 6,   TumCMig↓, 5,   TumCMig↑, 1,   TumCP↓, 7,   TumMeta↓, 1,   Twist↓, 1,   uPA↓, 4,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 3,   β-catenin/ZEB1↝, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ATF4↓, 1,   ATF4↑, 2,   EGFR↓, 7,   EGFR↝, 1,   eNOS↓, 1,   HIF-1↓, 3,   Hif1a↓, 5,   NO↑, 1,   VEGF↓, 6,   VEGF↝, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 6,   COX2↝, 1,   CXCR4↓, 2,   IKKα↓, 2,   IL6↓, 1,   IL6↝, 1,   Inflam↓, 1,   JAK↓, 2,   JAK1↓, 1,   JAK2↓, 1,   M2 MC↓, 1,   NF-kB↓, 10,   NF-kB↑, 1,   NF-kB↝, 1,   p65↓, 1,   PGE2↓, 2,   PSA↝, 1,   TNF-α↓, 1,   TNF-α↝, 1,  

Synaptic & Neurotransmission ⓘ

ADAM10↓, 1,   MAOA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↝, 1,   CDK6↓, 2,   CDK6↑, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 10,   Dose↑, 1,   Dose↝, 1,   Dose∅, 1,   eff↓, 3,   eff↑, 17,   eff↝, 1,   eff∅, 1,   Half-Life↝, 1,   RadioS↑, 5,   selectivity↑, 7,  

Clinical Biomarkers ⓘ

AR↝, 1,   BG↓, 3,   E6↓, 2,   E7↓, 2,   EGFR↓, 7,   EGFR↝, 1,   Ferritin↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 2,   IL6↓, 1,   IL6↝, 1,   Ki-67↓, 1,   LDH↓, 1,   LDH↑, 1,   Myc↓, 1,   PSA↝, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   ChemoSideEff↓, 3,   OS↑, 2,   QoL↑, 2,   RenoP↑, 1,   Risk↓, 2,   toxicity↓, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 320

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 6,   Catalase↑, 1,   GPx↑, 2,   GSH↑, 2,   H2O2↓, 1,   HO-1↑, 4,   lipid-P↓, 1,   MDA↓, 1,   MPO↓, 1,   NQO1↑, 2,   NRF2↑, 6,   ROS↓, 5,   mt-ROS↓, 1,   SOD↑, 4,  

Mitochondria & Bioenergetics ⓘ

Insulin↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

adiP↑, 1,   AMPK↑, 2,   p‑cMyc↑, 1,   FGF21↑, 1,   glucose↓, 2,   GlucoseCon↑, 1,   Glycolysis↑, 1,   H2S↑, 1,   HK2↑, 1,   LDL↓, 2,   NADPH↓, 1,   PFK↑, 1,   PKM2↑, 1,   PPARα↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↑, 1,   BAD↓, 1,   BAX↓, 1,   Casp3↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,   p16↓, 1,   P53↓, 1,  

Cell Cycle & Senescence ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   GSK‐3β↓, 1,   IGF-1↓, 1,   mTOR↓, 3,   p‑mTOR↑, 1,   PI3K↓, 1,   RAS↓, 1,  

Migration ⓘ

Ca+2↓, 1,   CDK5↓, 1,   TXNIP↓, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,   NO↓, 1,  

Barriers & Transport ⓘ

GLUT4↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CRP↓, 1,   IL10↑, 1,   IL17↓, 1,   IL1β↓, 1,   IL23↓, 1,   IL6↓, 1,   Inflam↓, 6,   MCP1↓, 1,   NF-kB↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BDNF↑, 1,   ChAT↑, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,   BACE↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   BioEnh↑, 1,   Dose↝, 3,   eff↑, 2,   Half-Life∅, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   cognitive↑, 3,   memory↑, 2,   neuroP↑, 6,   OS↑, 2,   toxicity↓, 1,   toxicity↑, 1,  
Total Targets: 90

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
17 Curcumin
14 Berberine
14 Quercetin
13 Baicalein
12 Fisetin
9 Thymoquinone
9 Resveratrol
8 Apigenin (mainly Parsley)
8 Magnetic Fields
8 Honokiol
8 Shikonin
7 Alpha-Lipoic-Acid
7 Artemisinin
7 EGCG (Epigallocatechin Gallate)
6 diet FMD Fasting Mimicking Diet
6 Lycopene
6 Sulforaphane (mainly Broccoli)
6 Urolithin
5 Chemotherapy
5 Capsaicin
5 Magnolol
5 Metformin
5 Piperlongumine
5 Rosmarinic acid
5 Silymarin (Milk Thistle) silibinin
4 Ashwagandha(Withaferin A)
4 Chlorogenic acid
4 Citric Acid
4 Piperine
4 Pterostilbene
3 5-fluorouracil
3 Coenzyme Q10
3 Astragalus
3 Cisplatin
3 brusatol
3 Carnosic acid
3 Chrysin
3 salinomycin
3 diet Short Term Fasting
3 Gambogic Acid
3 Hydrogen Gas
3 Magnetic Field Rotating
3 Naringin
2 Auranofin
2 Silver-NanoParticles
2 Allicin (mainly Garlic)
2 Betulinic acid
2 Brucea javanica
2 Boswellia (frankincense)
2 Carvacrol
2 Thymol-Thymus vulgaris
2 Propolis -bee glue
2 Calorie Restriction Mimetics
2 Ursolic acid
2 Dichloroacetate
2 Deguelin
2 Ellagic acid
2 HydroxyTyrosol
2 itraconazole
2 Juglone
2 Luteolin
2 Niclosamide (Niclocide)
2 doxorubicin
2 Plumbagin
2 Vitamin D3
1 Andrographis
1 2-DeoxyGlucose
1 Baicalin
1 Biochanin A
1 Bufalin/Huachansu
1 Butyrate
1 Trastuzumab
1 Celastrol
1 Hydroxycinnamic-acid
1 Spermidine
1 Aspirin -acetylsalicylic acid
1 Crocetin
1 diet Methionine-Restricted Diet
1 Emodin
1 Ferulic acid
1 flavonoids
1 Garcinol
1 HydroxyCitric Acid
1 Huperzine A/Huperzia serrata
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Laetrile B17 Amygdalin
1 Methylene blue
1 MCToil
1 Oleuropein
1 Oleocanthal
1 sericin
1 Phenethyl isothiocyanate
1 Parthenolide
1 Gold NanoParticles
1 Selenium
1 Selenium NanoParticles
1 Formononetin
1 acetazolamide
1 Selenite (Sodium)
1 Aflavin-3,3′-digallate
1 Vitamin C (Ascorbic Acid)
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:209  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page